Mankind Pharma shares rise after Kotak upgrades to Buy
Kotak Institutional Equities upgraded Mankind Pharma to “buy” from “add” and raised its target to Rs 3,000. Kotak forecasts EPS growth between FY26 and FY29.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.